Chest
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, C. D.
(Chest. 1999;116:461S-462S.)
© 1999 American College of Chest Physicians

Multimodality Therapy of Esophageal Cancer*

Cameron D. Wright, MD

* From General Thoracic Surgery, Massachusetts General Hospital, Boston, MA.

Correspondence to: Cameron D. Wright, MD, Massachusetts General Hospital, General Thoracic Surgery, Fruit Street, Boston, MA 02114; e-mail: wright.cameron{at}mgh.harvard.edu

Multimodality therapy of esophageal cancer has been evaluated in several clinical trials, with positive results in terms of improved survival compared with single-modality therapy. A case report is presented describing the use of paclitaxel in a multimodality regimen for a patient with a bulky esophageal tumor. In addition, results are described of a clinical trial in which patients received a paclitaxel-based regimen as part of multimodality therapy for esophageal cancer.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.